Corbus Pharmaceuticals (CRBP) has shared an update.
Corbus Pharmaceuticals Holdings, Inc. has approved new employment agreements for its CEO, Yuval Cohen, and CFO, Sean Moran, effective April 10, 2024, with a two-year term. Cohen will earn a base salary of $622,804, with potential bonuses and equity awards, and Moran will earn $463,455, also with incentives. Both agreements include non-compete and non-solicitation clauses, with specific severance benefits and COBRA coverage under certain termination conditions, including enhanced terms during a change in control period. These agreements include provisions for after-tax optimization and extend through April 10, 2026.
See more insights into CRBP stock on TipRanks’ Stock Analysis page.
